What development phase is Vectren in?

Vectren is FDA-approved (marketed).

What is the generic name of Vectren?

ISOXICAM is the generic (nonproprietary) name of Vectren.

Last reviewed 2026-04-20 · How we verify

Vectren (ISOXICAM)

FDA-approved withdrawn Small molecule Quality 15/100

Vectren (isoxicam) is a small molecule drug that targets prostaglandin G/H synthase 2, a key enzyme involved in inflammation. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation. Vectren is not FDA-approved, and its commercial status is unknown. It is used to treat various inflammatory conditions, but its specific indications are unclear. Vectren has a long half-life of 33 hours and high bioavailability of 97%.

At a glance

Generic name	ISOXICAM
Drug class	isoxicam
Target	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vectren CI brief — competitive landscape report
Vectren updates RSS · CI watch RSS